Wenzler E, et al. - Researchers sought to determine the pharmacokinetics, safety, and tolerability of intravenous (i.v.) fosfomycin disodium (ZTI-01) and oral fosfomycin tromethamine after a single dose in 28 healthy adult subjects. They noticed excretion of approximately 74% and 80% of the 1-g and 8-g i.v. doses unchanged in the urine by 48 h compared to 37% after oral administration, with the majority of this excretion occurring by 12 h regardless of dosage form. There appeared no new safety concerns during this study. Results supported further investigation of i.v. fosfomycin in the target patient population, including patients with complicated urinary tract infections and pyelonephritis.